Monday, November 21, 2016
Clinical Trials for Alzheimer’s Disease (CTAD) Selects Stemedica International to Present at Annual International Conference
Latest preclinical and clinical data regarding the effects of Stemedica’s proprietary stem cells on Alzheimer’s disease to be presented and discussed
San Diego, California and Lausanne, Switzerland — November 21, 2016
Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s disease (AD), is pleased to announce it will share its latest preclinical at the International Conference on Clinical Trials for Alzheimer’s Disease (CTAD). The 9th annual CTAD will be held December 8th-10th in San Diego, CA. CTAD gets together worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease therapies. On Friday, December 9th, a special conference symposium “Stem Cells for Alzheimer’s disease therapeutics”, moderated by Lon S. Schneider, MD, Keck School of Medicine of the University of Southern California, will include a presentation by Tristan Bolmont, PhD, Chief Scientist at Stemedica International, “Stem cells for Alzheimer’s disease: Abeta amyloidosis, tau pathology and gut microbiota.” The research shows that intravenous administration of Stemedica’s mesenchymal stem cells safely decrease aggregation of Ab and tau proteins, decrease neuroinflammation and modulate microglia activity in the brain without side effects such as microhemorrhages and cerebral amyloid angiopathy. Additionally, another paper by Dr. Bolmont on “Amelioration of gastro-intestinal microbiota following stem cell treatment in a mouse model of cerebral abeta amyloidosis” will be presented on December 10th at a poster session.
“Stemedica International is honored to be included in the very first presentation at CTAD of information about stem cells for the potential treatment of Alzheimer’s disease,” says Dr. Nikolai Tankovich, MD, PhD, Stemedica International’s Executive Chairman. “We are excited to share our unique and powerful results at such a prestigious venue.”
Stemedica International’s preclinical interventions demonstrate that Alzheimer’s disease pathology is amenable to its proprietary therapeutic stem cell intervention. Stemedica International is the first company in the United States to receive FDA IND approval for a Phase IIa clinical trial treating Alzheimer’s disease using stem cells.
The University of California, Irvine has begun dosing patients in this trial and is actively recruiting. More information including enrollment details, can be found at https://clinicaltrials.gov/ct2/show/NCT02833792?term=stemedica&rank=1.
About Stemedica International S.A.
Stemedica International S.A. is a biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer’s disease. The company is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells. Stemedica International has the worldwide rights to manufacture and distribute its parent company’s allogeneic, ischemia-tolerant mesenchymal stem cell (itMSC) and ischemia-tolerant neural stem cell (itNSC) lines and stem cell factors for Alzheimer’s disease. The company also has Swissmedic licenses to import, export and distribute Stemedica Cell Technologies’ cell lines worldwide for human use in approved clinical trials. Manufactured in compliance with cGMP standards, the stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. For more information, visit www.stemedica-intl.com.
About Stemedica Cell Technologies Inc.
Stemedica Cell Technologies Inc. is a global biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells and stem cell factors. The company is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging, ischemic stroke, Alzheimer’s disease and traumatic brain injury. Stemedica’s products are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California, and can be found online at www.stemedica.com.
Forward Looking Statements
This press release may contain forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements. These statements reflect the views of Stemedica as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Stemedica international, S.A.
David Cheatham, MBA
+41 (0)78 794 7232